Matthew Reilley
University of Virginia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Matthew Reilley as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:06 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07824960 · Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic AdenocarcinomaUniversity of Virginia · not yet recruiting · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:06 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.J Immunother Cancer · 2018224 citationsRCR 7.3
- Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.J Immunother Cancer · 201758 citationsRCR 1.6
- Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.J Immunother Cancer · 202338 citationsRCR 2.5
- A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.Clin Cancer Res · 202427 citationsRCR 3.0
- Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer.Oncologist · 202213 citationsRCR 0.7
- 13 citationsRCR 1.6
- Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.Oncologist · 20252 citationsRCR 0.4